Transaction News: Nasdaq-listed Insulet picks Malaysia for new RM878 million insulin plant

Nasdaq-listed Insulet Corporation, a US-based innovative medical device company has selected Gelang Patah in Johor, Malaysia for its new manufacturing facility to produce its Omnipod® Insulin Management System.
The new manufacturing facility will include approximately 400,000 square feet of manufacturing space. Insulet plans to invest approximately RM800 million over five years and hire more than 500 full-time employees once the facility is operating at full capacity.
Insulet was assisted in the legal aspects of establishing their Malaysian operations by Partners of Skrine, Fariz Abdul Aziz, Jesy Ooi, Shannon Rajan, Jillian Chia, Richard Khoo, Selvamalar Alagaratnam, and supported by Senior Associates, Manshan Singh, Tan Wei Xian and Rachel Chiah, and Associates, Jeremiah Ch’ng, Raaasi Laarnia, Jemima Tang and Vanessa Ho.
Media coverage of the transaction can be accessed at:

This alert contains general information only. It does not constitute legal advice nor an expression of legal opinion and should not be relied upon as such. For further information, kindly contact